| Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. | |
| | |
MedLine Citation:
|
PMID: 21091270 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To compare the efficacy and safety of olmesartan medoxomil (O) and ramipril (R) in elderly patients with essential arterial hypertension. METHODS: After a 2-week placebo washout, 351 elderly hypertensive patients aged 65-89 years (office sitting diastolic blood pressure, DBP, 90-109 mmHg and office sitting systolic blood pressure, SBP, 140-179 mmHg) were randomized double-blind to 12-week treatment with O 10 mg or R 2.5 mg once daily. After the first 2 and 6 weeks, doses could be doubled in non-normalized (blood pressure <140/90 mmHg for non-diabetic and <130/80 mmHg for diabetic) subjects, up to 40 mg for O and 10 mg for R. Office blood pressures were assessed at randomization, after 2, 6 and 12 weeks of treatment; 24-h ambulatory blood pressure (ABP) was recorded at randomization and after 12 weeks. RESULTS: At week 12, in the intention-to-treat population (170 patients O and 175 R) the rate of normalized subjects was significantly larger in the O group (38.8% vs 26.3% R; p = 0.013). Baseline-adjusted mean sitting office blood pressure reduction at final visit was not significantly greater under O [SBP: 16.6 (95% confidence interval 14.0/19.2) mmHg vs 13.0 (10.4/15.6) mmHg R, p = 0.206; DBP: 11.8 (10.3/13.3) mmHg vs 10.5 (9.0/12.0) mmHg, p = 0.351]. In the subgroup of patients with valid ABP recordings (38 O and 47 R), the reduction in 24-h average blood pressure was significantly (p < 0.01) larger with O [SBP: 8.9 (9.8/8.1) and DBP: 5.7 (6.3/5.1) mmHg] than with R [6.7 (7.9/5.6) and 4.4 (5.1/3.7) mmHg]. The superiority of O was particularly evident in the last 4 h from the dosing interval. The proportion of patients with drug-related adverse events was comparable in the two groups (4.0% O vs 4.5% R), as well as the number of patients discontinuing study drug because of a side-effect (8 O vs 7 R). CONCLUSIONS: In elderly patients with essential arterial hypertension, O provides an effective, prolonged and well tolerated blood pressure control, with significantly better blood pressure normalization than R and represents a useful option among first-line drug treatments of hypertension in this age group. |
| | |
Authors:
|
Jean-Michel Mallion; Stefano Omboni; John Barton; Walter Van Mieghem; Krzysztof Narkiewicz; Peter-Klaus Panzer; Juan García Puig; Christodoulos Stefanadis; Robert Zweiker; |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2010-11-23 |
Journal Detail:
|
Title: Blood pressure. Supplement Volume: 1 ISSN: 0803-8023 ISO Abbreviation: Blood Press Suppl Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-01-25 Completed Date: 2011-04-26 Revised Date: 2012-03-30 |
Medline Journal Info:
|
Nlm Unique ID: 9300787 Medline TA: Blood Press Suppl Country: England |
Other Details:
|
Languages: eng Pagination: 3-11 Citation Subset: IM |
Affiliation:
|
Cardiology and Arterial Hypertension, CHU de Grenoble, Grenoble, France. JMMallion@chu-grenoble.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Angiotensin II Type 1 Receptor Blockers / therapeutic use* Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Antihypertensive Agents / administration & dosage, adverse effects, therapeutic use* Blood Pressure / drug effects Blood Pressure Determination Blood Pressure Monitoring, Ambulatory Diastole / drug effects Double-Blind Method Female Humans Hypertension / drug therapy*, physiopathology Imidazoles / administration & dosage, adverse effects, therapeutic use* Male Ramipril / administration & dosage, adverse effects, therapeutic use* Systole / drug effects Tetrazoles / administration & dosage, adverse effects, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Imidazoles; 0/Tetrazoles; 144689-24-7/olmesartan medoxomil; 87333-19-5/Ramipril |
| Investigator | |
Investigator/Affiliation:
|
M Baghestanian / ; B Eber / ; R Zweiker / ; V Riegelnik / ; W Van Mieghem / ; J M Mallion / ; G DuCailar / ; P K Panzer / ; W R Kresse / ; O Carewicz / ; J Iserloh / ; K H Krause / ; E Prechtel / ; I F K Naudts / ; A Schmidt / ; U Zimmerman / ; E Borbas / ; D Kremastinos / ; H Triantafyllidi / ; C Stefanadis / ; J Barton / ; K Narkiewicz / ; M Chrostowska / ; P Napora / ; B Gornikiewicz-Brzezicka / ; I Graczak / ; J Klimkiewicz / ; M Jesewska / ; J L Palma Gamiz / ; J Olivan / ; J Garcia Puig / ; B Gil Extremera / ; P Jimenez Lopez / ; J Sobrino Martinez / ; M Jesus Adrian / ; A Coca / ; M Doménech / |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.
Next Document: Comparability of haemoglobin mass measured with different carbon monoxide-based rebreathing procedur...